Warm Autoimmune Hemolytic Anemia Clinical Trial
Official title:
Sirolimus in the Treatment of Refractory/Relapsed Warm Autoimmune Hemolytic Anemia (AIHA)： a Phase 2 Prospective Trial
Autoimmune hemolytic anemia (AIHA) is a rare and heterogeneous disorder characterized by the destruction of red blood cells through warm or cold antibodies. Glucocorticoid (combined with rituximab) is the first-line treatment. However, the recurrence rate is very high and some patients may not respond to steroids. Second-line therapies include cyclosporine A (CsA), cyclophosphamide, rituximab, azathioprine, and even splenectomy. Our previous study of sirolimus in refractory/relapsed AIHA and ES found an effective rate of 80%. Therefore, the investigators plan to explore the efficacy and safety of sirolimus in the treatment of refractory/relapsed wAIHA.
Based on the optimal autoantibody-RBC reactivity temperatures, AIHA is classified into warm type, cold type, and mixed type. AIHA can be further classified into primary or secondary in nature. Glucocorticoid (combined with rituximab) is the first-line treatment. However, the recurrence rate is very high and some patients may not respond to steroids. Second-line therapies include cyclosporine A (CsA), cyclophosphamide, rituximab, azathioprine, and even splenectomy. The refractory/relapsed wAIHA patients have increased cardiovascular events, increased opportunities for infections, decreased quality of life, and even death. A prospective multi-institutional trial in autoimmune cytopenia found that 8 of 10 patients with AIHA and Evans syndrome respond to sirolimus. Our previous study of sirolimus in refractory/relapsed AIHA and ES also found an effective rate of approximately 80%. Since sirolimus is cheap and accessible, our findings may reduce the economic burden of patients and be a guide on the selection of second-line treatment drugs in refractory/relapsed wAIHA and Evans syndrome. ;
| Status | Clinical Trial | Phase | |
|---|---|---|---|
| Recruiting |
NCT05786573 -
A Study of Obexelimab in Patients With Warm Autoimmune Hemolytic Anemia (SApHiAre)
|
Phase 3 | |
| Withdrawn |
NCT03965624 -
Efficacy and Safety of Ixazomib and Dexamethasone Refractory Autoimmune Cytopenia
|
Phase 2 | |
| Recruiting |
NCT05922839 -
Zanubrutinib in the Treatment of Relapsed/Refractory wAIHA
|
Phase 2 | |
| Completed |
NCT01181154 -
Rituximab in Auto-Immune Hemolytic Anemia
|
Phase 3 | |
| Recruiting |
NCT05757570 -
An Open-label Study of Povetacicept in Subjects With Autoimmune Cytopenias
|
Phase 1/Phase 2 | |
| Withdrawn |
NCT04256148 -
ALXN1830 in Patients With Warm Autoimmune Hemolytic Anemia
|
Phase 2 | |
| Terminated |
NCT03075878 -
A Safety Study of SYNT001 in Participants With Warm Autoimmune Hemolytic Anemia (WAIHA)
|
Phase 1/Phase 2 | |
| Withdrawn |
NCT04956276 -
Subcutaneous ALXN1830 in Adult Participants With Warm Autoimmune Hemolytic Anemia
|
Phase 2 | |
| Completed |
NCT03226678 -
Study to Assess the Safety, Tolerability, Efficacy and PK of APL-2 in Patients With Warm Type Autoimmune Hemolytic Anemia (wAIHA) or Cold Agglutinin Disease (CAD)
|
Phase 2 | |
| Recruiting |
NCT04119050 -
Efficacy and Safety of M281 in Adults With Warm Autoimmune Hemolytic Anemia
|
Phase 2/Phase 3 | |
| Terminated |
NCT04253236 -
To Assess the Efficacy and Safety of RVT-1401 in the Treatment of Warm Autoimmune Hemolytic Anemia (ASCEND-WAIHA).
|
Phase 2 | |
| Temporarily not available |
NCT05221619 -
Post-trial Access for Nipocalimab in Participants With Warm Autoimmune Hemolytic Anemia (wAIHA)
|